Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy

He, Yuqing; Lu, Meng‐Yao; Che, Jianfei; Chu, Qian; Zhang, Peng; Chen, Yuan

doi:10.3389/fonc.2021.716844

Cited by 20 publications

(18 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a personalized medicine setting, biomarkers will be used not only to identify risks and monitor cancer, but also to select treatment methods. As the number of models designed to identify and predict biomarker genes capable of identifying drug susceptibility continues to grow, a priority for future research should be the development of new therapies targeting specific pathways involved in the pathogenesis of HCC [ 41 , 42 , 43 ]. Among the challenges in the clinical diagnosis of liver cancer is identifying biomarkers that satisfy the criteria of specificity, ease of detection (noninvasiveness), and the ability to reflect different pathological phenomena (tumor stage, size, invasion degree, and patient survival rate) [ 44 ].…”

Section: The Role Of Biomarkers In Cancer Therapymentioning

confidence: 99%

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Huang

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

Liver cancer is one of the most lethal cancers in the world, mainly owing to the lack of effective means for early monitoring and treatment. Accordingly, there is considerable research interest in various clinically applicable methods for addressing these unmet needs. At present, the most commonly used biomarker for the early diagnosis of liver cancer is alpha-fetoprotein (AFP), but AFP is sensitive to interference from other factors and cannot really be used as the basis for determining liver cancer. Treatment options in addition to liver surgery (resection, transplantation) include radiation therapy, chemotherapy, and targeted therapy. However, even more expensive targeted drug therapies have a limited impact on the clinical outcome of liver cancer. One of the big reasons is the rapid emergence of drug resistance. Therefore, in addition to finding effective biomarkers for early diagnosis, an important focus of current discussions is on how to effectively adjust and select drug strategies and guidelines for the treatment of liver cancer patients. In this review, we bring this thought process to the drug resistance problem faced by different treatment strategies, approaching it from the perspective of gene expression and molecular biology and the possibility of finding effective solutions.

show abstract

Section: The Role Of Biomarkers In Cancer Therapymentioning

confidence: 99%

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Huang

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…The Neutrophil to Lymphocytes Ratio (NLR) has been used to evaluate the risk of mortality in patients with liver disease [ 45 , 46 ], and has also been tested as a prognostic biomarker for immunotherapy in several studies. A decline in the NLR in patients with HCC receiving anti PD-1 therapy was associated with a better response to treatment and improved survival [ 46 , 47 ].…”

Section: Traditional Non-invasive Biomarkers Of Response To Icismentioning

confidence: 99%

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives

Pallozzi

Tommaso

Maccauro

et al. 2022

Cancers

View full text Add to dashboard Cite

The treatment perspectives of advanced hepatocellular carcinoma (HCC) have deeply changed after the introduction of immunotherapy. The results in responders show improved survival compared with Sorafenib, but only one-third of patients achieve a significant benefit from treatment. As the tumor microenvironment exerts a central role in shaping the response to immunotherapy, the future goal of HCC treatment should be to identify a proxy of the hepatic tissue condition that is easy to use in clinical practice. Therefore, the search for biomarkers that are accurate in predicting prognosis will be the hot topic in the therapeutic management of HCC in the near future. Understanding the mechanisms of resistance to immunotherapy may expand the patient population that will benefit from it, and help researchers to find new combination regimens to improve patients’ outcomes. In this review, we describe the current knowledge on the prognostic non-invasive biomarkers related to treatment with immune checkpoint inhibitors, focusing on serological markers and gut microbiota.

show abstract

“…Even though early screening and multidisciplinary diagnosis of HCC have greatly improved, the survival rate of postoperative HCC patients remains unsatisfactory 1 . Recently, immune checkpoint blockade (ICB) therapy, specifically targeting PD-1/PD-L1, has brought revolutionary progress in the advanced HCC treatment 2 . Still, only a minority of HCC patients benefit from current ICB therapies.…”

Section: Introductionmentioning

confidence: 99%

A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma

Xie

Zhang

Sun

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-related immune checkpoint genes (CRICGs) in hepatocellular carcinoma remains to be further clarified. This study aimed to construct the prognostic CRICG signature to predict the immunotherapy response and outcomes of HCC patients. The co-expressed CRICGs were first screened through Pearson correlation analysis. Based on the least absolute shrinkage and selection operator-COX regression analyses, we identified a prognostic 5-CRICGs model, which closely correlates with poor outcomes, cancer development, and immune response to hepatocellular carcinoma. External validation was conducted using the GSE14520 dataset. Lastly, qRT-PCR was performed to determine the expression of the CRICGs in HCC. In summary, we developed and validated a novel prognostic CRICG model based on 5 CRICGs. This prognostic signature could effectively forecast the outcomes and immune response of HCC patients, which may serve as biomarkers for anticancer therapy.

show abstract

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy

Cited by 20 publications

References 158 publications

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives

A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma

Contact Info

Product

Resources

About